2Firsts Talks with Nancy Loucas, Asia-Pacific THR Leader: Giving a Voice to the Overlooked Consumer

Jun.18.2025
Ahead of the upcoming Global Forum on Nicotine (GFN), 2Firsts interviews Nancy Loucas, Executive Coordinator of CAPHRA, on why consumers must have a voice in tobacco harm reduction policymaking—and how she’s helping them speak up.

[By Taco Tuinstra | 2Firsts] Nancy Loucas: Helping Consumers Find Their Voice

 

As part of its media partnership with the Global Forum on Nicotine (GFN), scheduled for June 19-21 in Warsaw, 2Firsts reached out to several scheduled speakers, and asked them about their respective fields of expertise.

 

Nancy Loucas has been fighting for vapers’ rights to be able to access the tools they need to become smokefree and remain smoke free since 2015, when she co-founded the Aotearoa Vapers Community Advocacy in New Zealand.

 

She is also the executive director of the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), which supports consumer tobacco harm reduction (THR) advocacy organizations and activities throughout the Asia Pacific region and beyond.

 

Under Loucas’ leadership, CAPHRA established numerous initiatives to give a voice to the consumer, who she says is often overlooked in the debates. Such programs include the “Right2Vape” testimonial database (set up in collaboration with the Consumer Advocates for Smoke-free Alternatives Association in the United States) and the “Right2Switch” petition, which urges the World Health Organization to regulate based on science and include consumers into its decision-making process.

 

At the GNF, Loucas will be hosting a workshop to help consumers effectively communicate their message, which fits well with the overall conference theme of “Challenging Perceptions – Effective Communication for Tobacco Harm Reduction.” 2Firsts asked Loucas about her aspirations and the challenges facing consumers.

 

2Firsts Talks with Nancy Loucas, Asia-Pacific THR Leader: Giving a Voice to the Overlooked Consumer

Nancy Loucas | Image: AVCA

 

2Firsts: What inspired you to become a consumer advocate in the THR field?

 

Loucas: Watching relatives become ill and eventually die from smoking-related diseases. Watching relatives not receive appropriate medical care for nonsmoking-related illnesses, because of their smoking status. Not wanting my children to lose their mother, as I lost mine from smoking, at an early age. Wanting others to have the same opportunity I had to move off the deadly stuff.

 

2Firsts: How do you define THR, and why is the consumer perspective essential in this space?

 

Loucas: Short answer: My definition of THR is saving lives with innovation. Long answer: It is the prevention of smoking related death and disease through the use of innovative nicotine products that help people to move away from smoking and unsafe oral tobacco use.

 

2Firsts: What challenges do consumers face in communicating their positions?

 

Loucas: The main challenge is being listened to. The Machine, as I like to call tobacco control, likes to denigrate and dehumanize consumers and their lived experiences by labeling them as “anecdotes,” as opposed to scientists, experts or researchers. They do this by calling us names, accusing us of nefarious activities to the benefit of tobacco companies, and [by] excluding us from a seat at the table.

 

Another challenge arises from external NGO's [nongovernmental organizations] coming into countries without actually caring about that country, its culture or its problems, but only wanting to control the narrative with their views, their solutions, their policies. In Asia Pacific, a western mindset doesn't translate well at all.

 

2Firsts:What strategies have you found effective in elevating consumer perspectives in regulatory or scientific arenas?

 

Loucas:The one really good thing about the wider THR community is that the consumers, scientists and some regulatory people do communicate with respect and consideration. At conferences, everyone engages; the pro-THR scientists treat the consumers as equals.

 

In Asia Pacific—with the exception of Australia and India—there's less of a barrier between advocates on the one hand and public health and/or government on the other. That could be due to a number of factors, but I think it's mainly about networking in collective societies. Asia Pacific folks aren't very individualistic and going on about “my rights as an individual.” There are consumers who are on government committees about regulation; there are consumers who regularly engage with regulatory folks on a personal level.

 

The elevation of the consumer perspective is not so much the issue as is the backlash and misinformation from externally funded tobacco control-NGOs pushing a scripted narrative.

 

2Firsts:In your view, how can consumers be meaningfully involved in policy development on nicotine and tobacco products?

 

Loucas:Consumers can be—and should be—meaningfully involved in policy development as the decisions made directly impact them. The best way to do that is to engage. Some consumers are afraid they do not have the skills or the “right” to speak to policy/public health/government people, but with some support, some training and focus, they are the kingmakers really. My main comment to consumers who are reticent to engage is this "elected officials work for you, not the other way around.”

 

2Firsts:What are the primary benefits you hope participants will gain from your GFN workshop?

 

Loucas:The GFN is about learning, community and support. The workshop is about helping people succeed in their advocacy and feel supported and confident in their mission.

 

2Firsts has been a media partner of the Global Forum on Nicotine (GFN) for three consecutive years.


2Firsts welcomes article submissions, interview opportunities, or commentary. Please contact us at info@2firsts.com or connect with 2Firsts CEO Alan Zhao on LinkedIn here.

 

Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
RELX and UK e-liquid brand T-Juice have launched the Prime Pro × Red Astaire bundle in France, combining the RELX Prime Pro open-system pod device with T-Juice’s signature Red Astaire nicotine salt e-liquid. The collaboration retains the existing Prime Pro hardware platform while using an established flavor brand to create a complete open-system offering. The product appeared in French retail and distribution channels in August 2026 and represents a co-branded retail bundle rather than a new device launch.
Aug.27
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
From Border-Logistics Insiders to Retail Service Stations, Australia Mounts a Sweeping Crackdown on the Illicit Nicotine Trade as iGET Vapes Surface in A$80 Million Crime Networks
From Border-Logistics Insiders to Retail Service Stations, Australia Mounts a Sweeping Crackdown on the Illicit Nicotine Trade as iGET Vapes Surface in A$80 Million Crime Networks
Australian authorities have disclosed two major enforcement actions that go beyond product seizures and retail closures to examine how illicit tobacco and vape networks operate. On Aug. 14, the Multi Agency Strike Team said seven people had been charged and two criminal networks were valued by authorities at a combined A$80 million, or about US$56.8 million. Investigators allege the groups used bonded warehouses, freight businesses and “trusted insiders” in legitimate industries to circumvent border controls. In a separate operation on Aug. 11, more than 100 service stations were targeted as authorities sought information on illicit tobacco importation, distribution networks and the movement of sales proceeds.
Aug.17
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22